A key position to strengthen growth and commercial expansion in Europe
PARIS, February 01, 2022–(BUSINESS WIRE)–Regulatory news:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully automated solution for medical labs, is very pleased to announce that diagnostics industry expert Gabriel Plan is joining Ikonisys as as commercial director for the French market. Gabriel’s responsibilities will include accelerating sales of Ikoniscope20 in France and other French-speaking regions of Europe by acquiring new customers, top-tier KOLs (Key Opinion Leaders) and additional reference labs.
Gabriel brings to Ikonisys more than ten years of sales and marketing experience, all spent in the molecular diagnostics industry. Gabriel gained business expertise particularly at MP Biochemicals, a global supplier and manufacturer of life science, biochemical and diagnostic products. He started there as a sales representative, then moved on to marketing, then for several years was responsible for sales of diagnostics for Western Europe. Gabriel holds a master’s degree in molecular diagnostics and business management from Paris-Sud XI University.
“Gabriel is an important hire for Ikonisys as he brings additional business and technical knowledge to the area where we operate” noted Jurgen Schipper, Commercial Director of Ikonisys. “As Ikonisys is focused not only in the United States but also in Europe, Gabriel’s knowledge of the French market and his extensive commercial experience will accelerate the growth of Ikonisys in one of the most important global markets for Ikonisys” continued Jurgen Schipper.
“I am very honored to join Ikonisys and to be able to participate in the development and deployment of the company in Europe. Ikonisys is particularly well positioned to support French diagnostic laboratories in their process of expanding their business thanks to an unparalleled level of automated detection and analysis of rare tumor cells, and subsequent optimization of their workflow” declared Gabriel Plan, Sales Director France.
About Ikonisys
Ikonisys SA is a cell diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specializing in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully automated solution designed to provide accurate and reliable detection and analysis of rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. With its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on circulating tumor cells (CTCs).
For more information, visit www.Ikonisys.com
Warning
This press release contains forward-looking statements about the prospects and development of the Company. These statements are sometimes identified by the use of the future, conditional and forward-looking words such as “believe”, “aim”, “expect”, “intend”, “estimate”, “believe”. “, “should”, “could”, “will” or “will” or, where applicable, the negative form of these terms or any other variation or similar expression. This information is not historical data and should not be interpreted as a guarantee that the facts and data stated will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties related to the economic environment. , financial, competitive and regulatory This information contains data relating to the intentions, estimates and objectives of the Company concerning in particular the market, strategy, growth, results, financial situation and the Company’s cash. The forward-looking information contained in this press release speaks only as of the date of this press release. The Company does not undertake to update the forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all the risks, uncertainties or other factors that could affect its business, their potential impact on its business or the extent to which the materialization of a risk or of a combination of risks could cause the results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220201005868/en/
contacts
Iconic
Alessandro Mauri
CFO
[email protected]
NewCap
Olivier Bricaud / Louis-Victor Delouvrier
Investor Relations
[email protected]
Phone. :
NewCap
Nicolas Merigeau
Media Relations
[email protected]
Phone. :